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Abstract 20 
Equine multinodular pulmonary fibrosis (EMPF), a progressive fibrosing interstitial lung 21 
disease has been associated with γ-herpesviruses. This case series describes five horses 22 
with EMPF. Three horses were diagnosed with EMPF ante mortem with the typical 23 
clinical presentation including dyspnoea and weight loss. All died or had to be euthanised 24 
despite treatment with corticosteroids. Two horses were diagnosed with EMPF post 25 
mortem. They not only had EMPF but also concurrent other diseases.  EHV-5 DNA was 26 
identified in all horses by PCR.  27 
 28 
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Introduction 31 
Since 2007, when the pathology of equine multinodular pulmonary fibrosis (EMPF) was 32 
first described by Williams et al. (2007) multiple cases have been reported (Hart et al., 33 
2008, Wong et al., 2008, Poth et al., 2009, Niedermayer et al., 2010, Verryken et al., 34 
2010, Lehmbecker et al., 2011, Marenzoni et al., 2011, Schwarz et al., in press, Soare et 35 
al., 2011). All of these cases have been associated with the equine γ-herpesvirus EHV-5 36 
and in some cases additionally EHV-2 was present (Williams et al., 2007). Wong et al. 37 
(2009) have been the first to describe the typical history and predominant clinical signs of 38 
horses with EMPF. All of the reported cases had a history of either lethargy, weight loss, 39 
fever, cough, tachypnoea, respiratory distress or a combination of these symptoms 40 
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(Kubiski et al., 2008, Wong et al., 2008, Niedermayer et al., 2010, Verryken et al., 2010, 41 
Marenzoni et al., 2011, Soare et al., 2011, Schwarz et al., in press). The main clinical 42 
signs are tachycardia, tachypnoea, increased respiratory effort, lethargy, fever and nasal 43 
discharge (Kubiski et al., 2008, Wong et al., 2008, Niedermayer et al., 2010, Verryken et 44 
al., 2010). However, Niedermayer et al. (2010) reported two cases, in which additionally 45 
ulcerative keratopathy and oral ulcers, potentially γ-herpesvirus related symptoms were 46 
observed. Furthermore, cases, where EHV-5 seems to induce bone marrow pathology are 47 
described. Hart et al. (2008) report a case with pancytopenia and two cases have been 48 
described linking EMPF with leukaemia/lymphoma via EHV-5 (Schwarz et al., in press, 49 
Van der Werf et al., 2011). An induction of lymphoproliferative disease by EHV-5 in 50 
horses might occur similar to what is reported for Epstein-Barr Virus (EBV) in humans 51 
(Kawa, 2000). Main laboratory changes described with EMPF are hypoxaemia, 52 
leukocytosis due to mature neutrophilia, lymphopenia, anaemia and 53 
hyperfibrinogenaemia (Wong et al., 2008). Some horses also showed hypoalbuminaemia 54 
(Wong et al., 2008, Niedermayer et al., 2010). Typical lesions on thoracic radiographs 55 
and ultrasound compass a nodular interstitial pattern and a general roughening of the 56 
pleura with nodular lesions, respectively (Hart et al., 2008, Kubiski et al., 2008, Wong et 57 
al., 2008, Niedermayer et al., 2010, Verryken et al., 2010, Marenzoni et al., 2011, Soare 58 
et al., 2011). Ante mortem diagnosis is based on these results in combination with a 59 
positive EHV-5 PCR (from BALF) and exclusion of other pathological agents (Wong et 60 
al., 2008, Verryken et al., 2010) and can be proven by molecular and histopathological 61 
investigations of lung biopsies (Wong et al., 2008, Niedermayer et al., 2010). 62 
Macroscopically the discrete nodular form can be differentiated from the diffuse nodular 63 
 4 
form, which is reported to be the most common (Williams et al., 2007, Poth et al., 2009). 64 
In the diffuse nodular form the tan-white and firm nodules are small (< 5cm), but 65 
numerous and coalescing with discrete borders to generally rare unaffected lung tissue 66 
(Williams et al., 2007). The discrete nodular form is dominated by several similarly large 67 
nodules (up to 10 cm), embedded in grossly not affected lung parenchyma (Williams et 68 
al., 2007, Poth et al., 2009). In some horses enlargement of lung lymph nodes was found 69 
additionally (Williams et al., 2007, Poth et al., 2009), however generally pathological 70 
lesions are restricted to the lung (Williams et al., 2007).  71 
Histologically the disease is characterised by different stages of interstitial fibrosis and 72 
inflammation (Williams et al., 2007, Poth et al., 2009). Mature collagen deposition can be 73 
found in the interstitium (Williams et al., 2007, Poth et al., 2009). Alveoli are destroyed 74 
and replaced by alveolar-like structures lined by cuboidal cells (honeycombing) 75 
(Williams et al., 2007, Poth et al., 2009), which contain numerous inflammatory cells, 76 
predominantly neutrophils and macrophages (Williams et al., 2007). In some of these 77 
macrophages eosinophilic intranuclear inclusion bodies (Cowdry Type A) can be found 78 
(Williams et al., 2007, Poth et al., 2009). Furthermore, hypertrophy of type II 79 
pneumocytes is apparent (Williams et al., 2007, Poth et al., 2009). Rarely there is a 80 
deposition of immature collagen only causing destruction of the alveolar architecture, 81 
without the typical “honeycomb-formation” (Williams et al., 2007, Poth et al., 2009). 82 
Inflammatory components in the interstitium consist of lymphocytes, plasma cells, and 83 
neutrophils (Williams et al., 2007, Poth et al., 2009) but also multinucleated giant cells 84 
can be seen (Poth et al., 2009, Marenzoni et al., 2011). PCR for EHV-5 revealed positive 85 
results in 100 % of reported cases (Williams et al., 2007, Wong et al., 2008, Hart et al., 86 
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2008, Poth et al., 2009, Verryken et al., 2010, Marenzoni et al., 2011, Soare et al., 2011, 87 
Schwarz et al., in press). Williams et al. (2007) observed 33.3 % of horses additionally to 88 
be positive for EHV-2 by PCR.  89 
This case series describes three cases with the typical clinical presentation of EMPF 90 
described in the literature: dyspnoea and weight loss (Wong et al., 2008, Niedermayer et 91 
al., 2010, Verryken et al., 2010). All three were treated with corticosteroids but did not 92 
survive. Furthermore two cases were diagnosed with EMPF post mortem after they were 93 
euthanized/died due to an other than respiratory disease.  94 
 1 
Case reports 95 
Between November 2008 and August 2011 the three Equine Hospitals of the University 96 
of Veterinary Medicine Vienna (Austria), the University of Veterinary and 97 
Pharmaceutical Sciences, Brno (Czech Republic) and the Szent István University 98 
(Hungary) diagnosed seven cases with EMPF, five of which are presented in this case 99 
series.  100 
 101 
EMPF cases with typical clinical presentation 102 
 103 
Case 1  104 
History: An 8-year old Holsteiner mare which was used for show jumping started to 105 
show dyspnoea and nasal discharge and was treated with clenbuterol (Ventipulmin)
1
 106 
(0.008 μg/kg bwt per os, q. 12 h) and mucolytic mediation with bromhexidine 107 
(Bisolvon)
1 
(0.025 mg/kg bwt per os, q. 12 h) for suspected bronchitis. The horse seemed 108 
to improve but started to be mildly pyrexic (38.5°C) after 2 weeks. Oxytetracyclin 109 
(Engemycine)
2 
(10 mg/kg bwt i.v. q. 24 h) and gentamicin (Vetrigent 5)
3
 (6.6 mg/kg bwt 110 
i.v. q. 24 h) were added to the treatment regime. But over the next 3 weeks further 111 
symptoms, such as anorexia, weight loss, tachypnoe and dyspnoea were noted and the 112 
horse was referred. 113 
Clinical examination: At admission the horse was in a poor body condition with normal 114 
temperature (37.8°C), a heart rate of 40 beats/min and tachypnoea with 32 breaths/min 115 
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(see Fig. 1). Furthermore the horse showed a mild expiratory dyspnoea and was mildly 116 
dehydrated with pale mucous membranes and a CRT of 3 sec. Slight mucous, bilateral 117 
nasal discharge was observed. Thoracic auscultation revealed increased lung sounds and 118 
on the right side wheezes could be heard ventrally.  119 
Further examinations: Arterial blood gas analysis revealed hypoxaemia (pO2 75 120 
mmHg, rr 95-105 mmHg). Haematology and blood biochemistry showed a leucocytosis 121 
(23.1 x 10
9
/l, rr 5.0-10.0 x 10
9
/l) with mature neutrophilia (21.8 x 10
9
/l, rr 3.0-7.0 x 10
9
/l) 122 
and lymphopenia (0.73 x 10
9
/l, rr 1.0-4.5 x 10
9
/l) and hyperfibrinogenaemia (3.74 g/l, rr 123 
1.50-2.20 g/l). Endoscopy revealed moderate amounts of brownish mucus in the trachea, 124 
mildly injected mucous membranes and a mildly thickened septum. Tracheal wash 125 
cytology showed neutrophilic inflammation (85% neutrophils) and bacterial culture 126 
revealed Actinobacillus equuli. Therefore, a diagnosis of bacterial bronchitis was made 127 
and the horse treated with penicillin-streptomycin (Tardomyocel Comp. III.)
4
 (22,000 128 
IU/kg bwt bwt q. 48 h) and enrofloxacin (Baytril 10%)
4
 (5 mg/kg bwt i.v. q. 24 h) for 13 129 
days. Additionally, the horse received sucralphate (Alusulin tabl.)
5
 (1 g/kg bwt per os q. 6 130 
h), Vitamin C (Acidum ascorbicum)
6
 (10 g per os q. 24 h) and different NSAIDs 131 
(flunixin-meglumine, phenylbutazone, ibuprofen) as needed. As no improvement was 132 
noticed treatment was changed to trimethoprim-sulfadiazine (Equibactin vet.)
7
 (30 mg/kg 133 
bwt per os q. 12 h) and metronidazole (Supplin)
8
 (20 mg/kg bwt per os q. 12 h) for ten 134 
days. 135 
Clinical outcome: After 23 days of treatment the horse remained hypoxaemic (pO2 77 136 
mmHg, rr 95-105 mmHg). Leucocytosis (12.4 x 10
9
/l, rr 5.0-10.0 x 10
9
/l) had improved 137 
but the horse still showed a mature neutrophilia (11.1 x 10
9
/l, rr 3.0-7.0 x 10
9
/l). Bacterial 138 
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and fungal culture of a repeat tracheal wash was negative as was a PCR for Mycoplasma 139 
spp. Bronchoalveolar lavage was performed and showed 62% neutrophils. Erythrocytes 140 
and haemosiderophages indicated both, fresh and old bleeding. Furthermore, reactive 141 
macrophages were noted. Radiographs of the thorax showed a mixed bronchointerstitial 142 
pattern with 5-6 nodular densities with a diameter of up to 1.5 cm (see Fig. 2). 143 
Ultrasonography of the thorax showed a generalised pleural roughening with multiple 144 
comet tails and one subpleural hypoechogenic nodule with a diameter of 3.5 cm. An 145 
ultrasound-assisted Tru-cut lung biopsy was taken and confirmed the diagnosis of EMPF. 146 
Furthermore, EHV-5 PCR of BALF and lung biopsy was positive. The treatment regime 147 
was changed to acyclovir (Telviran)
9
 (20 mg/kg bwt per os q. 8 h) and pentoxifylline 148 
(Pentoxyl-EP)
10
 (8 mg/kg bwt per os q. 8 h) for 14 days. For the first four days the horse 149 
also received dexamethasone (CP-Dexamethason)
11
 (0.1 mg/kg bwt i.v. q. 24 h). After 150 
one week of antiviral therapy euthanasia was advised due to total anorexia and severe 151 
dyspnoea. The horse was fed via nasogastric tube and received oxygen supplementation 152 
intranasally, but over the next seven days the horse`s condition worsened until it died.  153 
 154 
Case 2 155 
History: A 6 year old Oldenburg stallion, used for show jumping started to show the first 156 
symptoms directly after a competition and 4 weeks before admission. The horse was 157 
anorexic and rapidly lost weight (approx. 100-150 kg). The last 2 weeks before admission 158 
he also had intermittent cough.  159 
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Clinical examination: On presentation the stallion was in a poor body condition (410 160 
kg) and was depressed. The heart rate was 44 beats/min, respiratory rate was 24 161 
breaths/min and rectal temperature 38.7°C. The horse showed bilateral serous nasal 162 
discharge, cough and a mild mixed dyspnoea. Thoracic auscultation revealed moderately 163 
increased lung sounds, but no wheezes or crackles. 164 
Further examinations: Arterial blood gas analysis showed a mild hypoxaemia with a 165 
pO2 of 94 mmHg (rr 95-105 mmHg). Haematology revealed a leucocytosis (16.6 x 10
9
/l, 166 
rr 5.0-10.0 x 10
9
/l) with mature neutrophilia (12.6 x 10
9
/l, rr 3.0-7.0 x 10
9
/l). Blood 167 
biochemistry showed a hypoalbuminaemia (23 g/l, rr 25-40 g/l) and 168 
hyperfibrinogenaemia (5.49 g/l, rr: 0.5 – 4 g/l). Endoscopy of upper and lower airways 169 
showed moderate amounts of mucus in the trachea, injected mucus membranes and a 170 
mildly thickened tracheal septum. Tracheal wash cytology showed a neutrophilic 171 
inflammation. Bacterial and fungal culture was negative. Cytological evaluation of BALF 172 
revealed 24% mainly non-degenerate neutrophils, 74% mononuclear cells, some mast 173 
cells (2%) and very few eosinophils.  Erythrophagocytosis and haemosiderophages 174 
indicated pulmonary haemorrhage. EHV5 PCR was positive, mycoplasma PCR negative. 175 
Thoracic radiographs showed a nodular interstitial pattern. Ultrasonography of the thorax 176 
revealed a generalised roughening of the pleura with multiple comet tail artefacts and 177 
multiple small nodular hypoechoic subpleural lesions.  178 
Clinical outcome: During hospitalisation the horse had no appetite and had to be fed via 179 
nasogastric tube. For seven days the horse was treated with flunixin-meglumine 180 
(Flunixin)
12
 (1,1mg/kg bwt i.v. q. 24 h), acetylcystein (ACC200 granulatum)
8
  (10 mg/kg 181 
bwt per os q. 12 h) and trimethoprim-sulfadiazine (Equibactin vet.)
7
 (30mg/kg bwt per os 182 
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q. 12 h). Clinically no significant changes were noted and the horse remained 183 
intermittently pyrexic up to 38.9°C. Additional thorax radiographs two days after 184 
admission and another 10 days later showed a change of the initially nodular interstitial 185 
pattern to a rather diffuse interstitial pattern. Haematology at that point still showed a 186 
mild leucocytosis (14.6 x 10
9
/l, rr 5.0-10.0 x 10
9
/l) with mature neutrophila (11.0 x 10
9
/l, 187 
rr 3.0-7.0 x 10
9
/l). Fibrinogen had returned to normal, but the horse remained 188 
hypoalbuminaemic (22 g/l, rr 25-40 g/l). When the results of bacteriological culture from 189 
the tracheal wash fluid and the positive EHV-5 PCR result from the BALF were received 190 
a suspected diagnosis of EMPF was made and the horse treated with acyclovir (Telviran)
9
 191 
(20 mg/kg bwt per os q. 8 h) and dexamethasone (CP-dexamethason)
11
 (0.05mg/kg bwt 192 
i.v. q. 24 h). But 2 days after the start of acyclovir therapy the horse was euthanized on 193 
the owner`s request.  194 
 195 
Case 3  196 
History: A 16-year old Furioso mare from Slovakia used for pleasure riding had shown 197 
intermittent chronic cough and dyspnoea with an increased abdominal effort for at least 198 
four years, which was suspected to be an RAO. Two weeks before admission the horse 199 
acutely showed severe dyspnoea with tachycardia (60/min) and tachypnoea (60/min) and 200 
fever (39.8°C) and was treated with dexamethasone (Colvasone)12 (0.1 mg/kg bwt i.v. 201 
once) and potentiated sulphonamides (Trimazine)
13
 (25 mg/kg bwt per os q. 12 h) for 202 
seven days. The horse`s condition only temporarily improved and it was therefore 203 
referred. 204 
 6 
Clinical examination: At admission the horse was in a poor body condition (463 kg). 205 
Temperature was 37.5°C, heart rate and respiratory rate were 60 beats/min and 66 206 
breaths/min, respectively. The horse was in severe respiratory distress with nasal 207 
discharge. Markedly increased lung sounds with crackles and wheezes were auscultated 208 
on both sides of the thorax.  209 
Further examinations: Oxygen saturation on the standing, non-sedated horse measured 210 
by pulse oxymetry was 60%. Haematology revealed leucocytosis (18.9 x 10
9
/l, rr 5.0-211 
10.0 x 10
9
/l) due to mature neutrophilia (14.3 x 10
9
/l, rr 3.0-7.0 x 10
9
/l). The horse was 212 
dehydrated with a haematocrit of 50%. Blood biochemistry showed an elevated 213 
fibrinogen concentration (5.56 g/l, rr 0.5 – 4 g/l). On endoscopic examination large 214 
amounts of viscous white mucus could be found in the entire airways, especially in the 215 
trachea. The tracheal septum was markedly thickened. Cytological evaluation of tracheal 216 
wash fluid predominantly showed neutrophils. Thoracic radiographs showed a marked 217 
bronchointerstitial pattern with many peribronchial cuffings. Ultrasonographic 218 
examination of the thorax revealed diffuse irregularities of the pleura and one 219 
hypoechogenic nodule (1.5 cm diameter) and echocardiographic findings consistent with 220 
a cor pulmonale. Differential diagnoses were acute exacerbation of RAO or severe lung 221 
disease of unknown aetiology. Due to the findings on blood work, ultrasound and 222 
radiography EMPF was considered likely.  223 
Clinical outcome: The horse received emergency treatment with dexamethasone 224 
(Dexadreson a.u.v. inj.)
14
 (0.1 mg/kg bwt i.v.), clenbuterol (Ventipulmin)
1
 (0.8 mg/kg 225 
bwt per os), bromhexin (Eres)
15
 (40 mg/kg bwt per os), continuous intranasal oxygen (9 226 
l/min) and finally atropine (Atropin Biotika)
16
 (2.5 mg i.v.). During the non-invasive 227 
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examination the status of the horse progressively worsened and approximately 90 228 
minutes after atropine administration the horse died.  229 
 230 
EMPF diagnosed at post mortem 231 
 232 
Case 4 233 
A 14 month old Arabian filly was admitted for evaluation of lethargy and severe 234 
anaemia, but died on the way to the clinic. The owner did not report any respiratory 235 
signs. 236 
 237 
Case 5  238 
A 2 year old Warmblood filly was admitted as an emergency case with neurological 239 
signs. The horse had no history of previous medical problems and was found recumbent 240 
in the field. After transport to the clinic in sternal recumbency the filly was not able to 241 
stand at admission and was placed in an Anderson sling. Neurological examination 242 
revealed an abnormal mentation and severe ataxia (5/5). Due to financial restraint no 243 
further examinations were performed. A traumatic brain injury was suspected and 244 
treatment started with fluid therapy, DMSO (1 g/kg bwt i.v. as 10% solution in 0.9% 245 
saline) and dexamethasone (Dexavana)
17
 (0.1 mg/kg bwt i.v.). After approximately 6 246 
hours the filly lost the menace response bilaterally and developed bilateral mydriasis, not 247 
responding to light. The filly was euthanized on the owner`s request.  248 
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 249 
Post mortem of all cases 250 
Gross pathology showed the discrete form of EMPF in three horses (cases 1, 4, 5). The 251 
lungs showed numerous, variably sized, homogeneously, grey-white coloured, dense, 252 
sharply demarcated nodules up to 6.5 cm and lungs did not collapse on opening of the 253 
thoracic cavity. Mediastinal and tracheobronchial lymph nodes were diffusely enlarged. 254 
Case 1 also showed signs of diffuse chronic pleuritis on the visceral pleura with short 255 
fibrinous tags in some areas and small amounts of purulent exsudate were present in 256 
some of the small airways. Furthermore the heart showed signs of right ventricular 257 
hypertrophy. 258 
Histopathologically the lung areas affected with interstitial fibrosis were sharply 259 
demarcated from unaffected parenchyma. Examination of the nodules revealed an 260 
extensive thickening and fibrosis of the interstitial tissue due to deposition of diffuse 261 
mature collagen and infiltrations by inflammatory cells, predominantly lymphocytes, 262 
which were most prominent in perivascular and interlobular spaces (see Fig. 4).  263 
“Alveolar-like” structures (“honeycombing”), lined by flat to cuboidal epithelial cells, 264 
contained a mixed inflammatory infiltrate. Within airways abundant detritus with 265 
numerous macrophages and neutrophil granulocytes, some multinucleated giant cells and 266 
rarely cells with intranuclear eosinophilic inclusion bodies (see Fig. 5) could be found 267 
additionally, except in case 1. In some areas a proliferation of type II pneumocytes was 268 
prominent within alveoli. EHV-5 PCR was positive in lung specimen of all three cases. 269 
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In case 1 pathological lesions were restricted to the lung and regional lymph nodes, 270 
whereas in the other two horses (case 4 and 5) additional pathology was found.  271 
In case 4 a severe anaemia was evident beside a haemorrhagic diathesis with petechial 272 
bleedings and subcutaneous oedema. Lymphatic organs such as lymph nodes, GALT, 273 
bone marrow and spleen revealed severe depletion of lymphocytes. Additionally larval 274 
cyathostominosis could be diagnosed and both parotid glands showed disseminated 275 
necrotic lesions. Necropsy of the spleen revealed abscesses up to 10 mm diameter and 276 
with bacteriological culture Streptococcus equi subsp. zooepidemicus could be isolated 277 
besides other bacteria. Furthermore two chondroids up to 10 mm within the guttural 278 
pouches were suggestive for strangles infection in the past. A severe combined 279 
immunodeficiency seemed rather unlikely with regard to the age of the filly, but an 280 
immune-mediated process, responsible for multifactorial disease, could not be ruled out 281 
and seemed likely. Equine infectious anaemia was excluded by Coggins test and PCR. 282 
EHV-5 could not be detected in bone marrow by PCR.  283 
Case 5 revealed a lymphoplasmohistiocytic panencephalomyelitis with accompanying 284 
leptomeningitis and foci of demyelination in the cerebellar white matter. Focal bleedings 285 
could be found oligofocally within medulla oblongata and lumbar spinal cord. 286 
Immunohistochemical examination of paraffin-embedded brain tissue against 287 
Rabiesvirus-, Suid Herpes-Virus-1, Borna-Disease-Virus, West-Nile-Virus-, Equine 288 
Herpes-Virus-1- and Tick-borne Encephalitis-Virus-antigen revealed negative results and 289 
aetiology of the panencephalomyelitis remained unclear. 290 
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In two horses (case 2 and 3) the diffuse form of EMPF was found with confluent areas of 291 
smaller nodules. In both cases an EHV-5 PCR of the lung tissue was positive, but 292 
inclusion bodies were not found in case 3. 293 
 294 
Discussion 295 
This case series describes five cases with EMPF, which occured in Austria, Hungary and 296 
Slovakia. EMPF therefore has to be included as differential diagnosis for horses with 297 
respiratory symptoms but also in cases with weight loss in this area. 298 
Horses with EMPF, which survived have been treated with steroids and acyclovir (Wong 299 
et al., 2008). Therefore in cases 1 and 2 the treatment regime was changed to acyclovir 300 
and corticosteroids once a diagnosis of EMPF was made. Case 1 finally was euthanized 301 
after the horse was not-responding to antiviral therapy after one week of medication. 302 
There are different possible reasons why this horse was not responding to antiviral 303 
therapy. First of all the pulmonary fibrosis probably already was in an advanced stage. 304 
Treatment might have been not effective due to the reported poor bioavailability of 305 
acyclovir (3-8%) (Wilkins et al., 2005, Bentz et al., 2006, Garré et al. 2007). Furthermore 306 
it is still not known if EHV-5 is susceptible to acyclovir. 307 
Although case 2 seemed to be quite early in the course of disease the owner opted for 308 
euthanasia, because of the poor prognosis of EMPF, high costs of antiviral medication 309 
and parenteral feeding due to complete anorexia. In cases like this a poor prognosis might 310 
therefore lead to a self-fulfilling prophecy.  311 
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Case 3 presented with acute respiratory distress and cardiovascular decompensation due 312 
to severe lung disease. Decompensated pulmonary hypertension with cor pulmonale is 313 
the end stage of disease and seems to be a poor prognostic indicator (Hart et al., 2008, 314 
Wong et al., 2008). This horse had a history of suspected RAO. Likely respiratory 315 
symptoms in the early stages of EMPF were attributed to RAO as reported in other cases 316 
with EMPF (Lehmbecker et al., 2011). A further difficulty diagnosing EMPF early might 317 
be the diagnosis of a bacterial bronchitis as in case 2 or other cases in the past (Wong et 318 
al., 2002, Marenzoni et al., 2011, Schwarz et al., in press). The horses are treated for what 319 
is thought the reason for the respiratory problems but in fact is a secondary bacterial 320 
infection. In the meantime progression of EMPF leads to worsening of clinical signs and 321 
therefore reevaluation of the patient with further diagnostics, like ultrasound, 322 
radiographs, bronchoalveolar lavage, EHV-5 PCR, etc. Once a diagnosis is made the 323 
disease might be already in an advanced stage and more difficult to treat successfully. 324 
Corticosteroids have been used to treat EMPF given their anti-inflammatory and anti-325 
fibrotic effect. But their immunosuppressive properties and hence possible promotion of 326 
viral replication are controversially discussed (Hart et al., 2008, Wong et al., 2008, 327 
Marenzoni et al., 2011). In idiopathic pulmonary fibrosis (IPF), a human disease 328 
associated with Epstein-Barr Virus (also a γ-herpesvirus), treatment with corticosteroids 329 
does not seem to have an advantage (Doran and Egan, 2005).  330 
Interestingly cases 4 and 5, even in an advanced stage of disease did not show respiratory 331 
symptoms noticed by the owners. Case 4 predominantly showed depression and anaemia, 332 
which led to spontaneous death. Case 5 was euthanized with acute neurological 333 
symptoms due to an idiopathic panencephalitis. Therefore even in cases where clear 334 
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respiratory signs are lacking EMPF could be an ongoing problem. It is questionable if the 335 
other diseases in these horses developed concurrently with EMPF or EHV-5 infection as 336 
a result of immunosuppression. Immunosuppression or an immunological predisposition 337 
with a different host response have been discussed in the aetiopathogenesis of EMPF 338 
(Hart et al., 2008) and in some cases – as case 5 – an association between EMPF and 339 
immunosuppression seems to be obvious. 340 
EHV-5 appears to induce pathology in the bone marrow (Hart et al., 2008, Schwarz et al., 341 
in press). Case 4 died of anaemia and haemorrhagic diathesis (thrombocytopenia) and 342 
lymphoid organs were noticed to be depleted of lymphocytes (lymphopenia). Although 343 
EHV-5 PCR in the bone marrow was negative in this horse, it seems to resemble the case 344 
described by Hart et al. (2008). However in that case bone marrow was EHV-5 PCR 345 
positive and viral inclusion bodies were found in the bone marrow. Similar to EBV 346 
inducing lymphoproliferative disease in humans, EHV-5 might be responsible for cases 347 
of leukaemia and lymphoma in horses (Schwarz et al., in press, van der Werf et al., 348 
2011). 349 
Similar to EBV, EHV-5 is also found in healthy individuals (Torfason et al., 2008) and 350 
therefore further research is needed to clarify the role of EHV-5 in both, 351 
lymphoproliferative diseases and EMPF.  352 
 353 
Conclusions 354 
EMPF also should be considered as a differential diagnosis for respiratory symptoms and 355 
weight loss in Eastern European countries. Further research on the role of 356 
 13 
immunosuppression in the pathogenesis of EHV-5 infection and EMPF is necessary to 357 
assess the benefit of corticosteroids in treatment of the disease. 358 
 359 
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Medicus Partner, Biatorbagy, Hungary 373 
8
Sandoz Pharma GmbH, Barleben, Germany 374 
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9
Egis, Budapest, Hungary 375 
10
Extractum Pharma, Budapest, Hungary 376 
11
CP-Pharma GmbH, Burgdorf, Germany 377 
12
Norbrook Laboratories Limited, Newry, Ireland 378 
13
Kela Lab, Belgium 379 
14
Intervet, Czech Republic 380 
15
Eres, Laboratorios Calier, Spain 381 
16
Hoechst Biotika, Slovakia 382 
17
Vana GmbH, Vienna, Austria
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Figure legends 457 
Fig. 1: 8 year old Holsteiner mare with EMPF (case 1). 458 
Fig. 2: Lateral radiographs of caudodorsal lung field of case 1. The radiograph displays a 459 
severe diffuse interstitial pattern of increased pulmonary density and nodular opacities. 460 
Fig. 3: Gross pathology of case 2: diffuse form of EMPF with small nodular areas of 461 
fibrosis 462 
Fig. 4: Histology of lung tissue: thickening of alveolar interstitial tissue due to fibrosis. 463 
Large amounts of detritus in airways.  464 
Fig. 5: Histology of lung tissue: intranuclear eosinophilic inclusion body.  465 
